These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9042908)

  • 21. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.
    Ford D; Easton DF; Peto J
    Am J Hum Genet; 1995 Dec; 57(6):1457-62. PubMed ID: 8533776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
    Blecharz P; Szatkowski W; Klimek M; Urbański K
    Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer.
    Heimdal K; Maehle L; Apold J; Pedersen JC; Møller P
    Eur J Cancer; 2003 Oct; 39(15):2205-13. PubMed ID: 14522380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.
    Newman B; Mu H; Butler LM; Millikan RC; Moorman PG; King MC
    JAMA; 1998 Mar; 279(12):915-21. PubMed ID: 9544765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.
    Kramer JL; Velazquez IA; Chen BE; Rosenberg PS; Struewing JP; Greene MH
    J Clin Oncol; 2005 Dec; 23(34):8629-35. PubMed ID: 16314625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
    Buffone A; Capalbo C; Ricevuto E; Sidoni T; Ottini L; Falchetti M; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Breast Cancer Res Treat; 2007 Dec; 106(2):289-96. PubMed ID: 17333342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
    Van Der Looij M; Szabo C; Besznyak I; Liszka G; Csokay B; Pulay T; Toth J; Devilee P; King MC; Olah E
    Int J Cancer; 2000 Jun; 86(5):737-40. PubMed ID: 10797299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.
    Johannsson O; Ostermeyer EA; Håkansson S; Friedman LS; Johansson U; Sellberg G; Brøndum-Nielsen K; Sele V; Olsson H; King MC; Borg A
    Am J Hum Genet; 1996 Mar; 58(3):441-50. PubMed ID: 8644702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.
    Liede A; Malik IA; Aziz Z; Rios Pd Pde L; Kwan E; Narod SA
    Am J Hum Genet; 2002 Sep; 71(3):595-606. PubMed ID: 12181777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clustering of individuals with both breast and ovarian cancer--a possible indicator of BRCA founder mutations.
    Einbeigi Z; Meis-Kindblom JM; Kindblom LG; Wallgren A; Karlsson P
    Acta Oncol; 2002; 41(2):153-7. PubMed ID: 12102159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
    Berry DA; Parmigiani G; Sanchez J; Schildkraut J; Winer E
    J Natl Cancer Inst; 1997 Feb; 89(3):227-38. PubMed ID: 9017003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of BRCA1 germline mutations in 45 German breast/ovarian cancer families.
    Hamann U; Häner M; Stosiek U; Bastert G; Scott RJ
    J Med Genet; 1997 Nov; 34(11):884-8. PubMed ID: 9391879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
    Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G;
    Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.